12S138: Cross-linking and Engineered Biologic Drugs for the Treatment of Autoimmune Diseases

Saturday, November 12, 2022

4:30 PM – 5:30 PM Eastern Time

Location: Room 201

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Anne Davidson, MBBS, FRACP

Feinstein Institutes for Medical Research
Manhasset, NY, United States

Disclosure(s): Alpine Immune Sciences: Officer or Board Member (Ongoing); Viela Bio: Consultant (Ongoing)

New technologies are allowing the construction of therapeutics that deliver or block signals to cells by crosslinking two cell surface molecules with disparate functions. This session will show how this technology is creating new therapeutics with the potential to block activating pathways or activate inhibitory pathways for the treatment of autoimmune diseases.

Learning Objectives:

Understand the potential use of bi-specific antibodies
Learn how inhibitory cross-linking of molecules that activate kinase pathways can turn off detrimental cell activation
Review how CAR-T technology can be applied to the treatment of autoimmune diseases

Presentations:

4:30 PM – 4:45 PM Eastern Time

Bispecific Antibodies: Design and Rationale
Virtual Speaker: Paul Parren, PhD – LAVA Therapeutics
4:45 PM – 4:50 PM Eastern Time

Q&A
4:50 PM – 5:05 PM Eastern Time

Engineering IL-2 for the Treatment of Autoimmune Diseases
Speaker: Thomas Malek, PhD – University of Miami
5:05 PM – 5:10 PM Eastern Time

Q&A
5:10 PM – 5:25 PM Eastern Time

Treatment of Autoimmune Disease With CART Cells
Speaker: Christoph Ellebrecht, MD – Penn Medicine
5:25 PM – 5:30 PM Eastern Time

Q&A